

UMR 1027 : Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps
Equipe Vieillissement - Axe MAINTAIN : MAintain Functions and INTrinsec capacities with Aging :
Preventive and Personalized INterventional Research

Articles dans des revues internationales ou nationales avec comité de lecture ou dans les bases de données internationales *Mise à jour janvier 2020*

2020

1. Cavedo E, Lista S, Khachaturian Z, Amouyel P, Herholz K, Jack Jr CR, Sperling R, Cummings J, Blennow K, O'Bryant S, Frisoni GB, Khachaturian A, Kivipelto M, Klunk W, Broich K, **Andrieu S**, Thiebaut de Schotten M, Mangin JF, Lammertsma AA, Johnson K, Teipel S, Drzezga A, Bokde A, Colliot O, Bakardjian H, Zetterberg H, Dubois B, Vellas B, Schneider LS, Hampel H. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. *J Prev Alzheimers Dis.* 2014;1(3):181–202. doi:10.14283/jpad.2014.32.
2. Khachaturian ZS, Petersen RC, Snyder PJ, Khachaturian AS, Aisen P, de Leon M, Greenberg BD, Kukull W, Maruff P, Sperling RA, Stern Y, Touchon J, Vellas B, **Andrieu S**, Weiner MW, Carrillo MC, Bain LJ. Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. *Alzheimers Dement.* 2011;7(2):127–132. doi:10.1016/j.jalz.2011.02.005.
3. Maltais M, de Souto Barreto P, Perus L, et al. Multidomain Alzheimer Preventive Trial/Data Sharing Alzheimer (MAPT/DSA) Study Group (**Andrieu S** collaborator). Prospective Associations Between Diffusion Tensor Imaging Parameters and Frailty in Older Adults [published online ahead of print, 2020 Jan 25]. *J Am Geriatr Soc.* 2020;10.1111/jgs.16343. doi:10.1111/jgs.16343.

2019

1. Andre L, Gallini A, Montastruc F, Coley N, Montastruc JL, Vellas B, **Andrieu S**, Gardette V; MAPT/DSA study group. Anticholinergic exposure and cognitive decline in older adults: effect of anticholinergic exposure definitions in a 3-year analysis of the multidomain Alzheimer preventive trial (MAPT) study. *Br J Clin Pharmacol.* 2019 Jan;85(1):71-99. doi: 10.1111/bcp.13734.
2. Bowman GL, Dodge HH, Guyonnet S, ..., **Andrieu S**, et al. MAPT/DSA Study Group. A blood-based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer prevention trial. *Alzheimers Dement (N Y).* 2019;5:953–963. Published 2019 Dec 28. doi:10.1016/j.trci.2019.11.004
3. Coley N, Ngandu T, Lehtisalo J, Soininen H, Vellas B, Richard E, Kivipelto M, **Andrieu S**; HATICE, FINGER, and MAPT/DSA groups. Adherence to multidomain interventions for dementia prevention: Data from the FINGER and MAPT trials. *Alzheimers Dement.* 2019 Jun;15(6):729-741. doi: 10.1016/j.jalz.2019.03.005.
4. Coley N, Rosenberg A, van Middelaar T, Soulier A, Barbera M, Guillemont J, Steensma J, Igier V, Eskelinen M, Soininen H, Moll van Charante E, Richard E, Kivipelto M, **Andrieu S**; MIND-AD; HATICE groups. Older Adults' Reasons for Participating in an eHealth Prevention Trial: A Cross-Country, Mixed-Methods Comparison. *J Am Med Dir Assoc.* 2019 Jul;20(7):843-849.e5. doi: 10.1016/j.jamda.2018.10.019.
5. Delrieu J, Payoux P, Carrié I, Cantet C, Weiner M, Vellas B, **Andrieu S**. Multidomain intervention and/or omega-3 in nondemented elderly subjects according to amyloid status. *Alzheimers Dement.* 2019. 15 (11), 1392-1401.

6. Gabelle A, Gutierrez LA, Jaussent I, Ben Bouallegue F, De Verbizier D, Navucet S, Grasselli C, Bennys K, Marelli C, David R, Mariano-Goulart D, **Andrieu S**, Vellas B, Payoux P, Berr C, Dauvilliers Y. Absence of Relationship Between Self-Reported Sleep Measures and Amyloid Load in Elderly Subjects. *Front Neurol.* 2019 Sep 13;10:989.
7. Gabelle A, Jaussent I, Bouallègue FB, Lehmann S, Lopez R, Barateau L, Grasselli C, Pesenti C, de Verbizier D, Béziat S, Mariano-Goulart D, Carlander B, Dauvilliers Y; Alzheimer's Disease Neuroimaging Initiative; Multi-Domain Intervention Alzheimer's Prevention Trial study groups (**Andrieu S** collaborator). Reduced brain amyloid burden in elderly patients with narcolepsy type 1. *Ann Neurol.* 2019 Jan;85(1):74-83. doi: 10.1002/ana.25373.
8. Gallini A, Yrondi A, Cantet C, Poncet M, Vellas B, Schmitt, **Andrieu S**. Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study. *J Nutr Health Aging.* 2019;23(9):805–812. doi:10.1007/s12603-019-1252-4
9. Giudici KV, de Souto Barreto P, Guerville F, Beard J, Araujo de Carvalho I, **Andrieu S**, Rolland Y, Vellas B; MAPT/DSA group. Associations of C-reactive protein and homocysteine concentrations with the impairment of intrinsic capacity domains over a 5-year follow-up among community-dwelling older adults at risk of cognitive decline (MAPT Study). *Exp Gerontol.* 2019 Nov;127:110716.
10. Herr M, Cesari M, Landre B, Ankri J, Vellas B, **Andrieu S**; MAPT/DSA Study Group. Factors associated with changes of the frailty status after age 70: Findings in the MAPT study. *Ann Epidemiol.* 2019 Jun;34:65-70.e1. doi: 10.1016/j.annepidem.2019.03.008.
11. Lilamand M, Cesari M, Cantet C, **Andrieu S**. Relationship between brain amyloid deposition and instrumental activities of daily living in older individuals: two analyses from the MAPT study. *Geriatr Psychol Neuropsychiatr Vieil.* 2019 Jun 1;17(2):211-220. doi: 10.1684/pnv.2019.0801.
12. Maltais M, de Souto Barreto P, Pothier K, Cantet C, **Andrieu S**, Rolland Y, Vellas B; MAPT/DSA Study Group. Lifestyle multidomain intervention, omega-3 supplementation, or both for reducing the risk of developing clinically relevant depressive symptoms in older adults with memory complaints? Secondary analysis from the MAPT trial. *Exp Gerontol.* 2019 Jun;120:28-34. doi: 10.1016/j.exger.2019.02.010.
13. Puymirat E, Cayla G, Cottin Y, Elbaz M, Henry P, Gerbaud E, Lemesle G, Popovic B, Labèque JN, Roubille F, **Andrieu S**, Farah B, Schiele F, Ferrières J, Simon T, Danchin N. Twenty-year trends in profile, management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: Data from the FAST-MI program 1995-2015. *Am Heart J.* 2019 May 16;214:97-106. doi: 10.1016/j.ahj.2019.05.007.
14. Rolland Y, Barreto PS, Maltais M, Guyonnet S, Cantet C, **Andrieu S**, Vellas B. Effect of Long-Term Omega 3 Polyunsaturated Fatty Acid Supplementation with or without Multidomain Lifestyle Intervention on Muscle Strength in Older Adults: Secondary Analysis of the Multidomain Alzheimer Preventive Trial (MAPT). *Nutrients.* 2019 Aug 16;11(8). pii: E1931.
15. Rouch L, Cestac P, Hanon O, Ruidavets JB, Ehlinger V, Gentil C, Cool C, Helmer C, Dartigues JF, Bouhanick B, Chamontin B, Sallerin B, Vellas B, Marquié JC, Esquirol Y, **Andrieu S**. Blood pressure and cognitive performances in middle-aged adults: the Aging, Health and Work longitudinal study. *J Hypertens.* 2019 Jun;37(6):1244-1253. doi: 10.1097/HJH.0000000000002013.
16. Soriano G, De Barreto PS, Rolland Y, Plessz M, Goisser S, Guyonnet S, Fougère B, Vellas B, **Andrieu S**, Sourdet S; Groupe DSA MAPT. Ready-meal consumption in older people: association with obesity and dietary intake. *Aging Clin Exp Res.* 2019 Jun;31(6):855-861. doi: 10.1007/s40520-018-1043-5.
17. Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, Kern S, Ousset PJ, Maruff P, Skoog I, Verhey FRJ, Freund-Levi Y, Tsolaki M, Wallin ÅK, Olde Rikkert M, Soininen H, Spiru L, Zetterberg H, Blennow K, Scheltens P, Muniz-Terrera G, Visser PJ; Alzheimer Disease Neuroimaging Initiative; AIBL Research Group; ICTUS/DSA study groups (**Andrieu S** collaborator). Duration of preclinical, prodromal, and

dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. *Alzheimers Dement.* 2019; 15 (7) : 888-898. doi:10.1016/j.jalz.2019.04.001

2018

1. Barbera M, Mangialasche F, Jongstra S, Guillemont J, Ngandu T, Beishuizen C, Coley N, Brayne C, **Andrieu S**, Richard E, Soininen H, Kivipelto M; HATICE study group. Designing an Internet-Based Multidomain Intervention for the Prevention of Cardiovascular Disease and Cognitive Impairment in Older Adults: The HATICE Trial. *J Alzheimers Dis.* 2018;62(2):649-663. doi: 10.3233/JAD-170858.
2. Barreto PS, Rolland Y, Cesari M, Dupuy C, **Andrieu S**, Vellas B; MAPT study group. Effects of multidomain lifestyle intervention, omega-3 supplementation or their combination on physical activity levels in older adults: secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT) randomised controlled trial. *Age Ageing.* 2018 Mar 1;47(2):281-288. doi: 10.1093/ageing/afx164.
3. Chhetri JK, de Souto Barreto P, Cantet C, Cesari M, Coley N, **Andrieu S**, Vellas B. Trajectory of the MAPT-PACC-Preclinical Alzheimer Cognitive Composite in the Placebo Group of a Randomized Control Trial: Results from the MAPT Study: Lessons for Further Trials. *J Prev Alzheimers Dis.* 2018;5(1):31-35. doi: 10.14283/jpad.2017.21.
4. Chhetri JK, de Souto Barreto P, Cantet C, Pothier K, Cesari M, **Andrieu S**, Coley N, Vellas B. Effects of a 3-Year Multi-Domain Intervention with or without Omega-3 Supplementation on Cognitive Functions in Older Subjects with Increased CAIDE Dementia Scores. *J Alzheimers Dis.* 2018;64(1):71-78. doi: 10.3233/JAD-180209.
5. Coley N, Raman R, Donohue MC, Aisen PS, Vellas B, **Andrieu S**. Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline? *J Nutr Health Aging.* 2018;22(8):982-998. doi: /10.1007/s12603-018-1052-2.
6. de Souto Barreto P, **Andrieu S**, Rolland Y, Vellas B; DSA MAPT Study Group. Physical activity domains and cognitive function over three years in older adults with subjective memory complaints: Secondary analysis from the MAPT trial. *J Sci Med Sport.* 2018 Jan;21(1):52-57. doi: 10.1016/j.jsams.2017.07.019.
7. de Souto Barreto P, Rolland Y, Cesari M, Dupuy C, **Andrieu S**, Vellas B; MAPT study group. Effects of multidomain lifestyle intervention, omega-3 supplementation or their combination on physical activity levels in older adults: secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT) randomised controlled trial. *Age Ageing.* 2018 Mar 1;47(2):281-288. doi: 10.1093/ageing/afx164.
8. Fougère B, de Souto Barreto P, Goisser S, Soriano G, Guyonnet S, **Andrieu S**, Vellas B; MAPT Study Group. Red blood cell membrane omega-3 fatty acid levels and physical performance: Cross-sectional data from the MAPT study. *Clin Nutr.* 2018 Aug;37(4):1141-1144. doi: 10.1016/j.clnu.2017.04.005.
9. Grimaldi-Bensouda L, Danchin N, Dallongeville J, Falissard B, Furber A, Cottin Y, Bonello L, Morel O, Leclercq F, Puymirat E, Ghanem F, Delarche N, Benichou J, Abenham L; PGRx-Acute Coronary Syndrome Study Group. (**Andrieu S**. collaborator). Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction. *Heart.* 2018 Oct;104(19):1583-1592. doi: 10.1136/heartjnl-2017-312534.
10. Krolak-Salmon P, Letrilliart L, Ceccaldi M, **Andrieu S**, Guérin O, Dubois B, Brochet B, Vandel P, Jeandel C, Leperre-Desplanques A, Clanet M, Druais PL. [Towards a national strategy on the diagnosis of neurocognitive disorders. A shared approach among the French National College of General Practitioners and specialists of neurocognitive disorders]. *Presse Med.* 2018 Jan;47(1):75-83. doi: 10.1016/j.patme.2017.10.029.
11. Leguelinel-Blache G, Castelli C, Roux-Marson C, Bouvet S, **Andrieu S**, Cestac P, Collomp R, Landais P, Loulière B, Mouchoux C, Varin R, Allenet B; MEDREV Working Group, Bedouch P, Kinowski JM. Impact of

collaborative pharmaceutical care on in-patients' medication safety: study protocol for a stepped wedge cluster randomized trial (MEDREV study). *Trials*. 2018 Jan 8;19(1):19. doi: 10.1186/s13063-017-2412-7.

12. Li J, Cesari M, Del Campo N, **Andrieu S**, Dong B, Lim WS, Vellas B. Impact of diabetes on caregiver stress in patients with Alzheimer's disease: data from the ICTUS study. *Int Psychogeriatr*. 2018 Aug;30(8):1109-1117. doi: 10.1017/S1041610217002460.
13. Lilamand M, Cesari M, Cantet C, Payoux P, **Andrieu S**, Vellas B; and the MAPT/DSA study group. Relationship Between Brain Amyloid Deposition and Instrumental Activities of Daily Living in Older Adults: A Longitudinal Study from the Multidomain Alzheimer Prevention Trial. *J Am Geriatr Soc*. 2018 Oct;66(10):1940-1947. doi: 10.1111/jgs.15497.
14. Moon SY, de Souto Barreto P, Cesari M, Chupin M, Mangin JF, Bouyahia A, Fillon L, **Andrieu S**, Vellas B. Physical Activity and Changes in White Matter Hyperintensities over Three Years. *J Nutr Health Aging*. 2018;22(3):425-430. doi: 10.1007/s12603-017-0959-3.
15. Moon SY, de Souto Barreto P, Chupin M, Mangin JF, Bouyahia A, Fillon L, **Andrieu S**, Vellas B. Association between Red Blood Cells Omega-3 Polyunsaturated Fatty Acids and White Matter Hyperintensities: The MAPT Study. *J Nutr Health Aging*. 2018;22(1):174-179. doi: 10.1007/s12603-017-0965-5.
16. Moon SY, de Souto Barreto P, Rolland Y, Chupin M, Bouyahia A, Fillon L, Mangin JF, **Andrieu S**, Cesari M, Vellas B; MAPT/DSA Study Group. Prospective associations between white matter hyperintensities and lower extremity function. *Neurology*. 2018 Apr 10;90(15):e1291-e1297. doi: 10.1212/WNL.0000000000005289.
17. Nourhashemi F, Hooper C, Cantet C, Féart C, Gennero I, Payoux P, Salabert AS, Guyonnet S, De Souto Barreto P, Vellas B; Multidomain Alzheimer Preventive Trial/Data sharing Alzheimer (DSA) study group (**Andrieu S**. collaborator). Cross-sectional associations of plasma vitamin D with cerebral β-amyloid in older adults at risk of dementia. *Alzheimers Res Ther*. 2018 Apr 25;10(1):43. doi: 10.1186/s13195-018-0371-1.
18. Rapp T, **Andrieu S**, Chartier F, Deberdt W, Reed C, Belger M, Vellas B. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study. *Value Health*. 2018 Mar;21(3):295-303. doi: 10.1016/j.jval.2017.09.019.
19. Rouch L, Cestac P, Sallerin B, **Andrieu S**, Bailly H, Beunardeau M, Cohen A, Dubail D, Hernandorena I, Seux ML, Vidal JS, Hanon O. Pulse Wave Velocity Is Associated With Greater Risk of Dementia in Mild Cognitive Impairment Patients. *Hypertension*. 2018 Nov;72(5):1109-1116. doi: 10.1161/HYPERTENSIONAHA.118.11443.
20. Soriano G, De Barreto PS, Rolland Y, Plessz M, Goisser S, Guyonnet S, Fougère B, Vellas B, **Andrieu S**, Sourdet S; Groupe DSA MAPT. Ready-meal consumption in older people: association with obesity and dietary intake. *Aging Clin Exp Res*. 2019 Jun;31(6):855-861. doi: 10.1007/s40520-018-1043-5.
21. Soriano G, Goisser S, Guyonnet S, Vellas B, **Andrieu S**, Sourdet S. Misreporting of Energy Intake in Older People: Comparison of Two Dietary Assessment Methods. *J Nutr Gerontol Geriatr*. 2018 Jul-Dec;37(3-4):310-320. doi: 10.1080/21551197.2018.1505578.
22. Tabue-Teguo M, Barreto de Souza P, Cantet C, **Andrieu S**, Simo N, Fougère B, Dartigues JF, Vellas B. Effect of Multidomain Intervention, Omega-3 Polyunsaturated Fatty Acids Supplementation or their Combinaison on Cognitive Function in Non-Demented Older Adults According to Frail Status: Results from the MAPT Study. *J Nutr Health Aging*. 2018;22(8):923-927. doi: 10.1007/s12603-018-1024-6.
23. van Middelaar T, Beishuizen CRL, Guillemont J, Barbera M, Richard E, Moll van Charante EP; HATICE consortium (**Andrieu S**. collaborator). Engaging older people in an internet platform for cardiovascular risk self-management: a qualitative study among Dutch HATICE participants. *BMJ Open*. 2018 Jan 21;8(1):e019683. doi: 10.1136/bmjopen-2017-019683.
24. Vellas B, Scrase D, Rosenberg GA, **Andrieu S**, Araujo de Carvalho I, Middleton LT. Editorial: WHO Guidelines on Community-Level Interventions to Manage Declines in Intrinsic Capacity: The Road for Preventing Cognitive Declines in Older Age? *J Prev Alzheimers Dis*. 2018;5(3):165-167. doi: 10.14283/jpad.2018.26.

25. Wargny M, Gallini A, Hanaire H, Nourhashemi F, **Andrieu S**, Gardette V. Diabetes Care and Dementia Among Older Adults: A Nationwide 3-Year Longitudinal Study. *J Am Med Dir Assoc.* 2018 Jul;19(7):601-606.e2. doi: 10.1016/j.jamda.2017.12.006.

2017

1. Aisen P, Touchon J, Amariglio R, **Andrieu S**, Bateman R, Breitner J, Donohue M, Dunn B, Doody R, Fox N, Gauthier S, Grundman M, Hendrix S, Ho C, Isaac M, Raman R, Rosenberg P, Schindler R, Schneider L, Sperling R, Tariot P, Welsh-Bohmer K, Weiner M, Vellas B. EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. *J Prev Alzheimers Dis.* 2017;4(2):116-124. doi: 10.14283/jpad.2017.13.
2. **Andrieu S**, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, Bories L, Cufi MN, Dantoin T, Dartigues JF, Desclaux F, Gabelle A, Gasnier Y, Pesce A, Sudres K, Touchon J, Robert P, Rouaud O, Legrand P, Payoux P, Caubere JP, Weiner M, Carrié I, Ousset PJ, Vellas B; MAPT Study Group. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. *Lancet Neurol.* 2017 May;16(5):377-389. doi: 10.1016/S1474-4422(17)30040-6.
3. Beishuizen CR, Coley N, Moll van Charante EP, van Gool WA, Richard E, **Andrieu S**. Determinants of Dropout and Nonadherence in a Dementia Prevention Randomized Controlled Trial: The Prevention of Dementia by Intensive Vascular Care Trial. *J Am Geriatr Soc.* 2017 Mar 6. doi: 10.1111/jgs.14834.
4. Bennys K, Gabelle A, Berr C, De Verbizier D, **Andrieu S**, Vellas B, Touchon J; MAPT-DSA Study group. Cognitive Event-Related Potential, an Early Diagnosis Biomarker in Frail Elderly Subjects: The ERP-MAPT-PLUS Ancillary Study. *J Alzheimers Dis.* 2017;58(1):87-97. doi: 10.3233/JAD-161012.
5. Coley N, **Andrieu S**; MAPT Study Group. Lessons from the Multidomain Alzheimer Preventive Trial - Authors' reply. *Lancet Neurol.* 2017 Aug;16(8):586. doi: 10.1016/S1474-4422(17)30226-0.
6. Dardenne S, Delrieu J, Sourdet S, Cantet C, **Andrieu S**, Mathiex-Fortunet H, Fougère B, Vellas B. Memory Complaints and Cognitive Decline: Data from the GUIDAGE Study1. *J Alzheimers Dis.* 2017;60(4):1567-1578. doi: 10.3233/JAD-170229.
7. de Mauléon A, Soto M, Kiyasova V, Delrieu J, Guignot I, Galtier S, Lilamand M, Cantet C, Lala F, Sastre N, **Andrieu S**, Pueyo M, Ousset PJ, Vellas B. The ROSAS Cohort: A Prospective, Longitudinal Study of Biomarkers for Alzheimer's Disease. Strategy, Methods and Initial Results. *J Prev Alzheimers Dis.* 2017;4(3):183-193. doi: 10.14283/jpad.2017.8.
8. de Souto Barreto P, Cesari M, **Andrieu S**, Vellas B, Rolland Y. Physical Activity and Incident Chronic Diseases: A Longitudinal Observational Study in 16 European Countries. *Am J Prev Med* 2017 Mar;52(3):373-378. doi: 10.1016/j.amepre.2016.08.028.
9. de Souto Barreto P, Cesari M, Rolland Y, Salabert AS, Payoux P, **Andrieu S**, Vellas B; MAPT Study Group.. Cross-Sectional and Prospective Associations Between β-Amyloid in the Brain and Chair Rise Performance in Nondementia Older Adults With Spontaneous Memory Complaints. *J Gerontol A Biol Sci Med Sci.* 2017 Feb;72(2):278-283. doi: 10.1093/gerona/glw195.
10. Escourrou E, Cesari M, Chicoulaa B, Fougère B, Vellas B, **Andrieu S**, Oustric S. How Older Persons Perceive the Loss of Independence: The Need of a Holistic Approach to Frailty. *J Frailty Aging.* 2017;6(2):107-112. doi: 10.14283/jfa.2017.3.
11. Fougère B, Goisser S, Cantet C, Soriano G, Guyonnet S, De Souto Barreto P, Cesari M, **Andrieu S**, Vellas B; MAPT Study Group. Omega-3 fatty acid levels in red blood cell membranes and physical decline over 3 years: longitudinal data from the MAPT study. 2017 Aug;39(4):429-437. doi: 10.1007/s11357-017-9990-x.
12. Gabelle A, Gutierrez LA, Jaussent I, Navucet S, Grasselli C, Bennys K, Marelli C, David R, **Andrieu S**, Berr C, Vellas B, Dauvilliers Y. Excessive Sleepiness and Longer Nighttime in Bed Increase the Risk of Cognitive

- Decline in Frail Elderly Subjects: The MAPT-Sleep Study. *Front Aging Neurosci.* 2017 Sep 28;9:312. doi: 10.3389/fnagi.2017.00312.
13. Gallini A, Coley N, **Andrieu S**, Lapeyre-Mestre M, Gardette V. Effect of dementia on receipt of influenza vaccine: a cohort study in French older adults using administrative data: 2007-2012. *Fundam Clin Pharmacol.* 2017 Aug;31(4):471-480. doi: 10.1111/fcp.12281.
 14. Hoevenaar-Blom MP, Guillemont J, Ngandu T, Beishuizen CRL, Coley N, Moll van Charante EP, **Andrieu S**, Kivipelto M, Soininen H, Brayne C, Meiller Y, Richard E. Improving data sharing in research with context-free encoded missing data. *PLoS One.* 2017 Sep 12;12(9):e0182362. doi: 10.1371/journal.pone.0182362. eCollection 2017.
 15. Hooper C, De Souto Barreto P, Coley N, Cantet C, Cesari M, **Andrieu S**, Vellas B. Cognitive Changes with Omega-3 Polyunsaturated Fatty Acids in Non-Demented Older Adults with Low Omega-3 Index. *J Nutr Health Aging.* 2017;21(9):988-993. doi: 10.1007/s12603-017-0957-5.
 16. Hooper C, De Souto Barreto P, Coley N, Caussé E, Payoux P, Salabert AS, Cesari M, **Andrieu S**, Bowman GL, Weiner M, Vellas B. Cross-Sectional Associations of Total Plasma Homocysteine with Cortical β -Amyloid Independently and as a Function of Omega 3 Polyunsaturated Fatty Acid Status in Older Adults at Risk of Dementia. *J Nutr Health Aging.* 2017;21(10):1075-1080. doi: 10.1007/s12603-017-0989-x.
 17. Hooper C, De Souto Barreto P, Coley N, Cesari M, Payoux P, Salabert AS, **Andrieu S**, Vellas B; MAPT/DSA Study Group. Cross-sectional Associations of Fatigue with Cerebral β -Amyloid in Older Adults at Risk of Dementia. *Front Med (Lausanne).* 2017 Nov 6;4:173. doi: 10.3389/fmed.2017.00173.
 18. Hooper C, De Souto Barreto P, Payoux P, Salabert AS, Guyonnet S, **Andrieu S**, Vellas B; MAPT/DSA study group. Cross-sectional associations of cortical β -amyloid with erythrocyte membrane long-chain polyunsaturated fatty acids in older adults with subjective memory complaints. *J Neurochem.* 2017 Aug;142(4):589-596. doi: 10.1111/jnc.14062.
 19. Hooper C, De Souto Barreto P, Payoux P, Salabert AS, Guyonnet S, **Andrieu S**, Sourdet S, Delrieu J, Vellas B. Association of Cortical β -Amyloid with Erythrocyte Membrane Monounsaturated and Saturated Fatty Acids in Older Adults at Risk of Dementia. *J Nutr Health Aging.* 2017;21(10):1170-1175. doi: 10.1007/s12603-017-0975-3.
 20. Jongstra S, Beishuizen C, **Andrieu S**, Barbera M, van Dorp M, van de Groep B, Guillemont J, Mangialasche F, van Middelaar T, Moll van Charante E, Soininen H, Kivipelto M, Richard E. Development and Validation of an Interactive Internet Platform for Older People: The Healthy Ageing Through Internet Counselling in the Elderly Study. *Telemed J E Health.* 2017 Feb;23(2):96-104. doi: 10.1089/tmj.2016.0066.
 21. Landi F, Cesari M, Calvani R, Cherubini A, Di Bari M, Bejuit R, Mshid J, **Andrieu S**, Sinclair AJ, Sieber CC, Vellas B, Topinkova E, Strandberg T, Rodriguez-Manas L, Lattanzio F, Pahor M, Roubenoff R, Cruz-Jentoft AJ, Bernabei R, Marzetti E; SPRINTT Consortium. he "Sarcopenia and Physical fRailty IN older people: multi-component Treatment strategies" (SPRINTT) randomized controlled trial: design and methods. *Aging Clin Exp Res.* 2017 Feb;29(1):89-100. doi: 10.1007/s40520-016-0715-2.
 22. Minois N, Lauwers-Cances V, Savy S, Attal M, **Andrieu S**, Anisimov V, Savy N. Using Poisson-gamma model to evaluate the duration of recruitment process when historical trials are available. *Stat Med.* 2017 Oct 15;36(23):3605-3620. doi: 10.1002/sim.7365.
 23. Moon SY, de Souto Barreto P, Chupin M, Mangin JF, Bouyahia A, Fillon L, **Andrieu S**, Vellas B; MAPT/DSA group. Associations between white matter hyperintensities and cognitive decline over three years in non-dementia older adults with memory complaints. *J Neurol Sci.* 2017 Aug 15;379:266-270. doi: 10.1016/j.jns.2017.06.031.
 24. Qualls C, Waters DL, Vellas B, Villareal DT, Garry PJ, Gallini A, **Andrieu S**. Reversible States of Physical and/or Cognitive Dysfunction: A 9-Year Longitudinal Study. *J Nutr Health Aging.* 2017;21(3):271-275. doi: 10.1007/s12603-017-0878-3.

25. Rouch L, Cestac P, Cool C, Helmer C, Dartigues JF, Berr C, Rouaud O, Vellas B, **Andrieu S**; REAL-FR Study Group and the 3C Study Group. Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer's Disease. *Curr Alzheimer Res.* 2017;14(3):255-267. doi: 10.2174/1567205013666161108114850.
26. Touchon J, Rosenbaum J, Aisen P, **Andrieu S**, Carrillo MC, Ceccaldi M, Dartiques JF, Feldman H, Gabelle A, Isaac M, Fitten LJ, Sperling RA, Vellas B, Tariot P, Weiner M. Editorial: Collaborative Efforts to Prevent Alzheimer's Disease. *J Nutr Health Aging.* 2017;21(10):1072-1074. doi: 10.1007/s12603-017-0961-9.
27. Vellas B, Fielding R, Bhasin S, Cerreta F, Goodpaster B, Guralnik JM, Kritchevsky S, Legrand V, Forkin C, Magaziner J, Morley JE, Rodriguez-Manas L, Roubenoff R, Studenski S, Villareal DT, Cesari M; International Conference on Frailtyand Sarcopenia Research Task Force (**Andrieu S** collaborator). Sarcopenia Trials in Specific Diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force. *J Frailty Aging.* 2016;5(4):194-200.

2016

1. Aisen P, Touchon J, **Andrieu S**, Boada M, Doody R, Nosheny RL, Langbaum JB, Schneider L, Hendrix S, Wilcock G, Molinuevo JL, Ritchie C, Ousset PJ, Cummings J, Sperling R, DeKosky ST, Lovestone S, Hampel H, Petersen R, Legrand V, Egan M, Randolph C, Salloway S, Weiner M, Vellas B. Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force. *J Prev Alzheimers Dis.* 2016;3(2):68-74. doi: 10.14283/jpad.2016.97.
2. Amieva H, Robert PH, Grandoulier AS, Meillon C, De Rotrou J, **Andrieu S**, Berr C, Desgranges B, Dubois B, Girtanner C, Joël ME, Lavallart B, Nourhashemi F, Pasquier F, Rainfray M, Touchon J, Chêne G, Dartigues JF. Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial. *Int Psychogeriatr.* 2016 May;28(5):707-17. doi: 10.1017/S1041610215001830.
3. **Andrieu S**, Coley N, Rolland Y, Cantet C, Arnaud C, Guyonnet S, Nourhashemi F, Grand A, Vellas B; PLASA group. Assessing Alzheimer's disease patients' quality of life: Discrepancies between patient and caregiver perspectives. *Alzheimers Dement.* 2016 Apr;12(4):427-37. doi: 10.1016/j.jalz.2015.09.003.
4. Barbat-Artigas S, Garnier S, Joffroy S, Riesco É, Sanguignol F, Vellas B, Rolland Y, **Andrieu S**, Aubertin-Leheudre M, Maurière P. Caloric restriction and aerobic exercise in sarcopenic and non-sarcopenic obese women: an observational and retrospective study. *J Cachexia Sarcopenia Muscle.* 2016 Jun;7(3):284-9. doi: 10.1002/jcsm.12075.
5. Beishuizen CR, Stephan BC, van Gool WA, Brayne C, Peters RJ, **Andrieu S**, Kivipelto M, Soininen H, Busschers WB, Moll van Charante EP, Richard E. Web-Based Interventions Targeting Cardiovascular Risk Factors in Middle-Aged and Older People: A Systematic Review and Meta-Analysis. *J Med Internet Res.* 2016 Mar 11;18(3):e55. doi: 10.2196/jmir.5218.
6. Coley N, Gallini A, Ousset PJ, Vellas B, **Andrieu S**; GuidAge study group. Evaluating the clinical relevance of a cognitive composite outcome measure: An analysis of 1414 participants from the 5-year GuidAge Alzheimer's prevention trial. *Alzheimers Dement.* 2016 Dec;12(12):1216-1225. doi: 10.1016/j.jalz.2016.06.002.
7. de Souto Barreto P, Delrieu J, **Andrieu S**, Vellas B, Rolland Y. Physical Activity and Cognitive Function in Middle-Aged and Older Adults: An Analysis of 104,909 People From 20 Countries. *Mayo Clin Proc.* 2016 Nov;91(11):1515-1524. doi: 10.1016/j.mayocp.2016.06.032.
8. del Campo N, Cesari M, Canevelli M, Hoogendoijk EO, Lilamand M, Kelaiditi E, Soto ME, Ousset PJ, Weiner MW, **Andrieu S**, Vellas B; ICTUS and REAL.FR/DSA groups. Refining Mild-to-Moderate Alzheimer Disease Screening: A Tool for Clinicians. *J Am Med Dir Assoc.* 2016 Oct 1;17(10):913-20. doi: 10.1016/j.jamda.2016.06.005.

9. del Campo N, Payoux P, Djilali A, Delrieu J, Hoogendoijk EO, Rolland Y, Cesari M, Weiner MW, **Andrieu S**, Vellas B; MAPT/DSA Study Group. Relationship of regional brain β -amyloid to gait speed. *Neurology*. 2016 Jan 5;86(1):36-43. doi: 10.1212/WNL.0000000000002235..
10. Delrieu J, **Andrieu S**, Pahor M, Cantet C, Cesari M, Ousset PJ, Voisin T, Fougère B, Gillette S, Carrie I, Vellas B. Neuropsychological Profile of "Cognitive Frailty" Subjects in MAPT Study. *J Prev Alzheimers Dis*. 2016 Jun;3(3):151-159.
11. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, **Andrieu S**, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genton R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O'Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR Jr; Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on "The Preclinical State of AD"; July 23, 2015; Washington DC, USA. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. *Alzheimers Dement*. 2016 Mar;12(3):292-323. doi: 10.1016/j.jalz.2016.02.002.
12. Fougère B, Aubertin-Leheudre M, Vellas B, **Andrieu S**, Demougeot L, Cluzan C, Cesari M. Clinical research for older adults in rural areas: the MINDED study experience. *Age (Dordr)*. 2016 Apr;38(2):30. doi: 10.1007/s11357-016-9892-3.
13. Genolini C, Ecochard R, Benghezal M, Driss T, **Andrieu S**, Subtil F. kmlShape: An Efficient Method to Cluster Longitudinal Data (Time-Series) According to Their Shapes. *PLoS One*. 2016 Jun 3;11(6):e0150738. doi: 10.1371/journal.pone.0150738. eCollection 2016.
14. Kelaiditi E, **Andrieu S**, Cantet C, Vellas B, Cesari M; ICTUS/DSA Group. Frailty Index and Incident Mortality, Hospitalization, and Institutionalization in Alzheimer's Disease: Data From the ICTUS Study. *J Gerontol A Biol Sci Med Sci*. 2016 Apr;71(4):543-8. doi: 10.1093/gerona/glv137.
15. Kelaiditi E, Canevelli M, **Andrieu S**, Del Campo N, Soto ME, Vellas B, Cesari M; Impact of Cholinergic Treatment Use Study/DSA Group. Frailty Index and Cognitive Decline in Alzheimer's Disease: Data from the Impact of Cholinergic Treatment USE Study. *J Am Geriatr Soc*. 2016 Jun;64(6):1165-70. doi: 10.1111/jgs.13956.
16. Kenigsberg PA, Aquino JP, Bérard A, Gzil F, **Andrieu S**, Banerjee S, Brémont F, Buée L, Cohen-Mansfield J, Mangialasche F, Platel H, Salmon E, Robert P. Dementia beyond 2025: Knowledge and uncertainties. *Dementia (London)*. 2016 Jan;15(1):6-21. doi: 10.1177/1471301215574785.
17. Lilamand M, Cesari M, Del Campo N, Cantet C, Soto M, Ousset PJ, Payoux P, **Andrieu S**, Vellas B; MAPT Study Group. Brain Amyloid Deposition Is Associated With Lower Instrumental Activities of Daily Living Abilities in Older Adults. Results From the MAPT Study. *J Gerontol A Biol Sci Med Sci*. 2016 Mar;71(3):391-7. doi: 10.1093/gerona/glv155.
18. Richard E, Jongstra S, Soininen H, Brayne C, Moll van Charante EP, Meiller Y, van der Groep B, Beishuizen CR, Mangialasche F, Barbera M, Ngandu T, Coley N, Guillemont J, Savy S, Dijkgraaf MG, Peters RJ, van Gool WA, Kivipelto M, **Andrieu S**. Healthy Ageing Through Internet Counselling in the Elderly: the HATICE randomised controlled trial for the prevention of cardiovascular disease and cognitive impairment. *BMJ Open*. 2016 Jun 10;6(6):e010806. doi: 10.1136/bmjopen-2015-010806.
19. Vellas B, Fielding R, Bhasin S, Cerreta F, Goodpaster B, Guralnik JM, Kritchevsky S, Legrand V, Forkin C, Magaziner J, Morley JE, Rodriguez-Manas L, Roubenoff R, Studenski S, Villareal DT, Cesari M; International Conference on Frailty and Sarcopenia Research Task Force (**Andrieu S** collaborator). Sarcopenia Trials in Specific Diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force. *J Frailty Aging*. 2016;5(4):194-200.
20. Winblad B, Amouyel P, **Andrieu S**, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, Georges J, Graff C, Iqbal K, Jessen F, Johansson G,

Jönsson L, Kivipelto M, Knapp M, Mangialasche F, Melis R, Nordberg A, Rikkert MO, Qiu C, Sakmar TP, Scheltens P, Schneider LS, Sperling R, Tjernberg LO, Waldemar G, Wimo A, Zetterberg H. Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol. 2016 Apr;15(5):455-532. doi: 10.1016/S1474-4422(16)00062-4.

2015

1. **Andrieu S**, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol. 2015 Sep;14(9):926-44. doi: 10.1016/S1474-4422(15)00153-2.
2. Coley N, Gallini A, **Andrieu S**. Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics. CNS Drugs. 2015 Jul;29(7):519-28. doi: 10.1007/s40263-015-0256-9.
3. Coley N, Gallini A, Garès V, Gardette V, **Andrieu S**; ICTUS/DSA group A Longitudinal Study of Transitions Between Informal and Formal Care in Alzheimer Disease Using Multistate Models in the European ICTUS Cohort. J Am Med Dir Assoc. 2015 Dec;16(12):1104.e1-7. doi: 10.1016/j.jamda.2015.09.010.
4. Coley N, Vaurs C, **Andrieu S**. Nutrition and Cognition in Aging Adults. Clin Geriatr Med. 2015 Aug;31(3):453-64. doi: 10.1016/j.cger.2015.04.008.
5. de Souto Barreto P, **Andrieu S**, Payoux P, Demougeot L, Rolland Y, Vellas B; Multidomain Alzheimer Preventive Trial/Data Sharing Alzheimer Study Group. Physical Activity and Amyloid- β Brain Levels in Elderly Adults with Intact Cognition and Mild Cognitive Impairment. J Am Geriatr Soc. 2015 Aug;63(8):1634-9. doi: 10.1111/jgs.13530.
6. Di Stefano F, Epelbaum S, Coley N, Cantet C, Ousset PJ, Hampel H, Bakardjian H, Lista S, Vellas B, Dubois B, **Andrieu S**; GuidAge study group. Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. J Alzheimers Dis. 2015;48(3):793-804. doi: 10.3233/JAD-150013.
7. Fougère B, Vellas B, **Andrieu S**, Demougeot L, Cluzan C, Cesari M. [Difficulties encountered and solutions provided in the implementation of a multidisciplinary intervention for the prevention of dependency in the older population in rural areas: the MINDED study]. Geriatr Psychol Neuropsychiatr Vieil. 2015 Sep;13(3):259-64. doi: 10.1684/pnv.2015.0566.
8. Gallini A, Gardette V, Lapeyre-Mestre M, de Souto Barreto P, Vellas B, **Andrieu S**, Rolland Y. Dementia Diagnosis and Influenza Vaccination in French Nursing Home Residents. J Am Geriatr Soc. 2015 Jun;63(6):1256-8. doi: 10.1111/jgs.13515.
9. Gallini A, Gardette V, Oumouhou N, **Andrieu S**, Donohue JM. Evolution of general practitioners' preferences for antipsychotics in France, 2003-2010. Psychiatr Serv. 2015 Apr 1;66(4):434-7. doi: 10.1176/appi.ps.201400020.
10. Garès V, **Andrieu S**, Dupuy JF, Savy N. An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials. Stat Med. 2015 Feb 20;34(4):541-57. doi: 10.1002/sim.6366.
11. Grotz C, Letenneur L, Bonsang E, Amieva H, Meillon C, Quertermont E, Salmon E, Adam S; ICTUS/DSA group. (**Andrieu S** collaborator). Retirement age and the age of onset of Alzheimer's disease: results from the ICTUS study. PLoS One. 2015 Feb 25;10(2):e0115056. doi: 10.1371/journal.pone.0115056. eCollection 2015.
12. Kenigsberg PA, Aquino JP, Bérard A, Gzil F, **Andrieu S**, Banerjee S, Brémond F, Buée L, Cohen-Mansfield J, Mangialasche F, Platel H, Salmon E, Robert P. Dementia beyond 2025: Knowledge and uncertainties. 2016 Jan;15(1):6-21. doi: 10.1177/1471301215574785.
13. Payoux P, Delrieu J, Gallini A, Adel D, Salabert AS, Hitzel A, Cantet C, Tafani M, De Verbizier D, Darcourt J, Fernandez P, Monteil J, Carrié I, Voisin T, Gillette-Guyonnet S, Pontecorvo M, Vellas B, **Andrieu S**. Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings. Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1459-68. doi: 10.1007/s00259-015-3067-9.

14. Rapp T, Vellas B, **Andrieu S**, Chartier F, Baraille L, Belger M. Observational Study of Resource use and Cost of Alzheimer's Disease in Europe (Geras) - 18-Month Results from the French Cohort. *Value Health*. 2015 Nov;18(7):A409. doi: 10.1016/j.jval.2015.09.971.
15. Rouch L, Cestac P, Hanon O, Cool C, Helmer C, Bouhanick B, Chamontin B, Dartigues JF, Vellas B, **Andrieu S**. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. *CNS Drugs*. 2015 Feb;29(2):113-30. doi: 10.1007/s40263-015-0230-6.
16. Rouch L, Cestac P, Hanon O, Cool C, Helmer C, Bouhanick B, Chamontin B, Dartigues J, Vellas B, **Andrieu S**. CO-13: Temporal evolution of cognitive changes in hypertension and potential effect modification by antihypertensive treatment status. VISAT cohort study. *Ann Cardiol Angeiol (Paris)*. 2015 Dec;64 Suppl 1:S8. doi: 10.1016/S0003-3928(16)30013-0.
17. Scherrer B, **Andrieu S**, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Vellas B. Analysing Time to Event Data in Dementia Prevention Trials: The Example of the GuidAge Study of EGb761®. *J Nutr Health Aging*. 2015;19(10):1009-11. doi: 10.1007/s12603-015-0582-0.
18. Soto M, **Andrieu S**, Gares V, Cesari M, Gillette-Guyonnet S, Cantet C, Vellas B, Nourhashémi F. Living Alone with Alzheimer's Disease and the Risk of Adverse Outcomes: Results from the Plan de Soin et d'Aide dans la maladie d'Alzheimer Study. *J Am Geriatr Soc*. 2015 Apr;63(4):651-8. doi: 10.1111/jgs.13347.
19. Sourdet S, Lafont C, Rolland Y, Nourhashemi F, **Andrieu S**, Vellas B. Preventable Iatrogenic Disability in Elderly Patients During Hospitalization. *J Am Med Dir Assoc*. 2015 Aug 1;16(8):674-81. doi: 10.1016/j.jamda.2015.03.011.
20. Weuve J, Proust-Lima C, Power MC, Gross AL, Hofer SM, Thiébaut R, Chêne G, Glymour MM, Dufouil C; MELODEM Initiative (**Andrieu S** collaborator) Guidelines for reporting methodological challenges and evaluating potential bias in dementia research. *Alzheimers Dement*. 2015 Sep;11(9):1098-109. doi: 10.1016/j.jalz.2015.06.1885.